Top

Published in:

01-09-2008 | Editorial Commentary

Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease

Authors: Michael Zeisberg, Raghu Kalluri

Published in: Pediatric Nephrology | Issue 9/2008

Abstract

Bone morphogenic protein-7 (BMP7) is a morphogen that is important for kidney development and which is also an integral part of the kidney’s physiological response to repair of acute kidney injury. Several studies demonstrate that preexisting renal BMP7 pathways can be utilized by administering recombinant BMP7 to protect the kidney in experimental models of chronic kidney disease (CKD). Effectiveness of recombinant BMP7 in animal studies raises the possibility that the BMP7 pathway could be equally utilized to treat patients with CKD and interstitial fibrosis. However, regulation of BMP7 activity in the kidney is complex. BMP7 activity in the kidney is not only determined by availability of BMP7 itself, but also by a balance of agonists, such as Kielin/chordin-like protein (KCP) or BMP receptors, and antagonists including gremlin, noggin, or uterine sensitization-associated gene-1 (USAG-1). Presence of BMP7 agonists and antagonists has to be considered when recombinant BMP7 is supplemented to treat injured kidneys. Here we summarize recent insights into the role of BMP7 in acute and chronic kidney injury and discuss the implications for future directions of antifibrotic therapies.

Zeisberg M (2006) Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 21:568–573CrossRef

Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J (2000) Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279:F130–143CrossRef

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968CrossRef

Sugimoto H, Grahovac G, Zeisberg M, Kalluri R (2007) Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56:1825–1833CrossRef

Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, Kalluri R (2003) Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 285:F1060–1067CrossRef

Ducy P, Karsenty G (2000) The family of bone morphogenetic proteins. Kidney Int 57:2207–2214CrossRef

Hogan BL (1996) Bone morphogenetic proteins in development. Curr Opin Genet Dev 6:432–438CrossRef

Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH, Corbett CC, Özkaynak E, Oppermann H, Rueger DC (1992) Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267:20352–20362CrossRef

Swencki-Underwood B, Mills JK, Vennarini J, Boakye K, Luo J, Pomerantz S, Cunningham MR, Farrell FX, Naso MF, Amegadzie B (2008) Expression and characterization of a human BMP-7 variant with improved biochemical properties. Protein Expr Purif 57:312–319CrossRef

10.

Wetzel P, Haag J, Campean V, Goldschmeding R, Atalla A, Amann K, Aigner T (2006) Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int 70:717–723CrossRef

11.

Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R (2006) Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 17:2504–2512CrossRef

12.

Mitu GM, Wang S, Hirschberg R (2007) BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 293:F1641–1648CrossRef

13.

Zeisberg M, Shah AA, Kalluri R (2005) Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280:8094–8100CrossRef

14.

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961CrossRef

15.

Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM, Dressler GR (2005) Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 11:387–393CrossRef

16.

Bosukonda D, Shih MS, Sampath KT, Vukicevic S (2000) Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys. Kidney Int 58:1902–1911CrossRef

17.

Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstatter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G (2007) Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int 71:325–335CrossRef

18.

Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O’Meara Y, Schmid H, Henger A, Kretzler M, Droguett A, Mezzano S, Brady HR (2005) Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45:1034–1039CrossRef

19.

Martin P, Parkhurst SM (2004) Parallels between tissue repair and embryo morphogenesis. Development 131:3021–3034CrossRef

20.

Gould SE, Day M, Jones SS, Dorai H (2002) BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61:51–60CrossRef

Title: Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease
Authors: Michael Zeisberg
Raghu Kalluri
Publication date: 01-09-2008
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 9/2008
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-008-0818-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2008

Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome

The role of dexamethasone on decreasing urinary cytokines in children with acute pyelonephritis

Obstacles to the prescribing of growth hormone in children with chronic kidney disease

Vitamin E administration at the onset of fever prevents renal scarring in acute pyelonephritis

Nephronophthisis-like nephritis associated with fibrous dysplasia of bone

Therapies for steroid-resistant nephrotic syndrome